The Diabetics Exposed to Telmisartan And Enalapril (DETAIL) trial is thus the first to show that an ARB offers renoprotection that is clinically equivalent to that of an ACE inhibitor.

Telmisartan, explained Bakris, is the longest-acting ARB, and there are clear differences in binding to the AT 1 receptor, with approximately 25% greater binding of telmisartan compared with losartan.

In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo.

More information: Mary M. McDermott et al, Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease, JAMA (2022).DOI: 10.1001/jama.2022.16797. Marc P ...

To the Editor: Barnett et al. (Nov. 4 issue)1 compared telmisartan and enalapril in type 2 diabetic nephropathy, without reporting or adjusting for certain major risk factors associated with diabe ...

The TRANSCEND (Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease) study enrolled nearly 6,000 people worldwide who are intolerant to ACE inhibitors ...